CD79A and metastatic neoplasm: The data thus far support the hypothesis that in mouse models of metastatic disease, the tumor can increase expression of CD79a on immature myeloid cells, thereby maintaining a more immature phenotype with immunosuppressive and tumor promoting characteristics.